Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Kínai posztoperatív CRSwNP-betegek klinikai eredményeinek és életminőségének vizsgálata (PREDICT)

2026. szeptember 22. frissítette: AstraZeneca

PREDICT: A Prospective, Multicenter Real-World Study to Describe the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients

This is a prospective, multicenter real-world observational study designed to describe post-operative outcomes, quality of life, disease control, recurrence-related characteristics, economic burden and post-operative treatment patterns in Chinese patients with CRSwNP undergoing endoscopic sinus surgery (ESS).

A tanulmány áttekintése

Állapot

Aktív, nem toborzó

Részletes leírás

This is a prospective, multicenter real-world observational study designed to describe post-operative outcomes, quality of life, disease control, recurrence-related characteristics, economic burden and post-operative treatment patterns in Chinese patients with CRSwNP undergoing endoscopic sinus surgery (ESS). Patients will receive standard medical care as determined by the treating physician at each site and, where possible, undergo scheduled study assessments that coincide with routine follow-up.

Approximately 200 patients diagnosed with CRSwNP by physicians and scheduled for surgical treatment will be enrolled from ~20 sites across different regions of China.

Potential participants will be identified during a screening period of up to 4 weeks before surgery. Participants who meet the eligibility criteria, provide informed consent, and undergo ESS during the screening period will be enrolled.

After enrolment, participants will undergo 52 weeks of post-operative follow-up. Planned follow-up timepoints are week 4 (Visit 2), week 12 (Visit 3), week 24 (Visit 4), week 36 (Visit 5), and week 52 (Visit 6). Follow-up data will be obtained from medical records, routine clinical assessments, and participant-reported questionnaires.

Tanulmány típusa

Megfigyelő

Beiratkozás (Tényleges)

146

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

      • Changchun, Kína, 130033
        • Research Site
      • Changsha, Kína
        • Research Site
      • Chengdu, Kína, 610078
        • Research Site
      • Guangzhou, Kína
        • Research Site
      • Guangzhou, Kína, 510062
        • Research Site
      • Guangzhou, Kína, 514700
        • Research Site
      • Haikou, Kína, 570311
        • Research Site
      • Kunming, Kína
        • Research Site
      • Nanchang, Kína
        • Research Site
      • Nanjing, Kína
        • Research Site
      • Nanning, Kína, 530021
        • Research Site
      • Qingdao, Kína
        • Research Site
      • Shanghai, Kína, 200031
        • Research Site
      • Shenzhen, Kína
        • Research Site
      • Wuhan, Kína
        • Research Site
      • Wuhan, Kína, 430000
        • Research Site
      • Xiamen, Kína, 361003
        • Research Site
      • Ürümqi, Kína, 830054
        • Research Site
    • Guangdong
      • Guangzhou, Guangdong, Kína, 518106
        • The Seventh Affiliated Hospital Sun Yat-sen University
    • Liaoning
      • Shenyang, Liaoning, Kína, 110002
        • Shengjing Hospital of China Medical University
    • Shandong
      • Jinan, Shandong, Kína, 250012
        • QiLu Hospital of Shandong University

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

  • Gyermek
  • Felnőtt
  • Idősebb felnőtt

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Mintavételi módszer

Valószínűségi minta

Tanulmányi populáció

Chinese CRSwNP Patients

Leírás

Inclusion Criteria:

  1. Participant must be 16 years of age or older, at the time of signing the informed consent.
  2. Participants with a documented diagnosis of bilateral CRSwNP.
  3. ESS is performed during the screening period.
  4. Voluntarily participate and sign the ICF.
  5. No history or current psychiatric disorders, with normal cognitive functions including understanding, expression, and orientation.

Exclusion Criteria:

  1. Any significant disease or disorder that the investigator believes may place the patient at risk or may affect the study results or the patient's ability to participate in the study.
  2. Use of biologic therapy for CRSwNP within 3 months prior to surgery.
  3. Currently participating in an interventional study.
  4. Patients who are unable to independently complete questionnaires due to language barriers or mental status.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Megfigyelési modellek: OTHER
  • Időperspektívák: PROSPECTIVE

Kohorszok és beavatkozások

Csoport / Kohorsz
Beavatkozás / kezelés
CRSwNP Registry Cohort

This is a prospective, multicenter real-world observational study .Patients will receive standard medical care as determined by the treating physician according to routine clinical practice at each site. No treatment assignment will be made as part of the study.

Patients will receive standard medical care as determined by the treating physician according to routine clinical practice at each site. No treatment assignment will be made as part of the study.

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
The observed value and change from baseline in SNOT-22 total score at week-52
Időkeret: baseline-week52

To describe the Sino-Nasal Outcome Test (SNOT)-22 total score at 52 weeks post- operatively.

[SNOT-22: score 0-5 each item, 5 means worse outcome, 22 items totally]

baseline-week52
The observed value and change from baseline in MLK score at week-52
Időkeret: baseline-week52

To describe the Modified Lund-Kennedy (MLK) score at 52 weeks post-operatively. [MLK score: score 0-24, 24 means worse outcome]

baseline-week52

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
The observed values and changes from baseline at each collection point: VAS - Total sinus symptoms item
Időkeret: baseline-week52

To describe the changes in post-operative symptom by Visual Analogue Scale(VAS) total sinus symptoms .

[VAS: score 0-10, 10 indicates worse outcome]

baseline-week52
The observed values and changes from baseline in NPS at each collection point
Időkeret: baseline-week52

To describe the changes in post-operative by Nasal Polyp Score (NPS). [NPS: score 0-4, 4 indicates worse outcome]

baseline-week52
The observed values and changes from baseline at each collection point: VAS - Nasal blockage item
Időkeret: baseline-week52

To describe the changes in post-operative symptom by Visual Analogue Scale(VAS) Nasal blockage item .

[VAS: score 0-10, 10 indicates worse outcome]

baseline-week52
The observed values and changes from baseline at each collection point: SNOT-22 Smell/taste Item Score
Időkeret: baseline-week52

To describe the changes in post-operative symptom by Sinonasal outcome test-22(SNOT-22) Smell/taste Item Score.

[SNOT-22: score 0-5 for each item, 5 means worse outcome]

baseline-week52
The observed values and changes from baseline at each collection point: SNOT-22 Nasal Congestion Item Score
Időkeret: baseline-week52

To describe the changes in post-operative symptom by Sinonasal outcome test-22(SNOT-22) Nasal Congestion Item Score.

[SNOT-22: score 0-5 for each item, 5 means worse outcome]

baseline-week52
The observed values and changes from baseline at each collection point: Nasal Congestion Score (NCS)
Időkeret: baseline-week52

To describe the changes in post-operative symptom by Nasal Congestion Score(NCS).

[NCS: score 0-3, 3 indicates worse outcome]

baseline-week52
The observed values and changes from baseline at each collection point: Loss of Smell
Időkeret: baseline-week52

To describe the changes in post-operative symptom by Loss of Smell Item Score. [ Loss of Smell : score 0-3 for each item, 3 means worse outcome]

baseline-week52
The observed values and changes from baseline at each collection point: Nasal Airway Resistance (NAR)
Időkeret: baseline-week52

To describe the changes in post-operative symptom by Nasal Airway Resistance(NAR).

baseline-week52
Pre-operative, 24-week post-operatively, and 52- week post-operative Lund-Mackay CT Scores.
Időkeret: week0-52

To describe the changes in post-operative CT Scores

week0-52
The observed values and cChanges from baseline at each collection point: SF-36((Short Form Health Survey)
Időkeret: baseline-week52

To describe the changes in post-operative Quality of Life by SF-36((Short Form Health Survey), which is a widely used questionnaire to measure health-related quality of life.

baseline-week52
The observed values and changes from baseline at each collection point: The SNOT-22 top five items' frequency counts and average score
Időkeret: baseline-week52

To describe the changes in post-operative Quality of Life by Sinonasal outcome test-22(SNOT-22) top five items' frequency counts and average score.

[SNOT-22: score 0-5 for each item, 5 means worse outcome]

baseline-week52
The observed values and changes from baseline at each collection point: SNOT-22 sleep domain
Időkeret: baseline-week52

To describe the changes in post-operative Sleep Quality [SNOT-22: score 0-5 for each item, 5 means worse outcome]

baseline-week52
Intranasal corticosteroids (INCS): the proportion of participants using INCS.
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by the proportion of participants using Intranasal corticosteroids (INCS).

week0-52
The daily dosage of participants used Systemic glucocorticoids (SCSs) for CRSwNP
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• The daily dosage (convert according to the equivalent dose of prednisone.) of participants used Systemic glucocorticoids (SCSs) for CRSwNP

week0-52
Proportion of participants who used Antibiotics for CRSwNP at least once
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• Proportion of participants who used Antibiotics for CRSwNP at least once.

week0-52
Proportion of participants who used biologics for CRSwNP at least once
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• Proportion of participants who used at least once.

week0-52
Proportion of participants who used ICS/LABA for asthma at least once.
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by

• Proportion of participants who used at least once.

week0-52
Proportion of other related medications used.
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively.

week0-52
The proportion of participants requiring surgery within one year and the number of surgery
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively.

week0-52
Time to first recurrence
Időkeret: week0-52

To describe the time to first recurrence and proportion of participants with recurrence

week0-52
Proportion of participants with recurrence
Időkeret: week0-52

To describe the time to first recurrence and proportion of participants with recurrence

week0-52
Proportion of participants demonstrating clinically meaningful improvement at Week 52 and Week 4 postoperatively based on: -NCS (MCID relative to pre-operative of -1.0)
Időkeret: week0-52

To describe the proportion of post-operative participants demonstrating clinically meaningful improvement at Week-52 and Week-4

week0-52
Proportion of participants demonstrating clinically meaningful improvement at Week 52 and Week 4 postoperatively based on: - SNOT-22 total score (with a Minimum Clinically Important Difference (MCID) relative to pre-operative of -8.9)
Időkeret: week0-52

To describe the proportion of post-operative participants demonstrating clinically meaningful improvement at Week-52 and Week-4 [SNOT-22: score 0-5 for each item, 5 means worse outcome]

week0-52
Proportion of participants demonstrating clinically meaningful improvement at Week 52 and Week 4 postoperatively based on: - VAS for nasal blockage item (MCID relative to pre-operative of -3)
Időkeret: week0-52

To describe the proportion of post-operative participants demonstrating clinically meaningful improvement at Week-52 and Week-4 [VAS scale: 0-10,10 means worse outcome]

week0-52
The proportion of participants with post-operative complications
Időkeret: week0-52

Post-operative complications by

•The proportion of participants with complications.

week0-52
Changes from baseline at each collection point: Spirometry (pre-BD FEV1)
Időkeret: baseline-week52

To describe asthma-related outcomes (for asthma participants only)

baseline-week52
Changes from baseline at each collection point: Asthma Control Questionnaire-5(ACQ-5)
Időkeret: baseline-week52

To describe asthma-related outcomes (for asthma participants only) [ACQ-5: score 0-6 for each item, 6 means worse outcome]

baseline-week52
Pre-operative, 24-week post-operatively, and 52-week ethmoid/maxillary sinuses (E/M) ratio
Időkeret: week0-52

To describe the changes in post-operative ethmoid/maxillary sinuses (E/M) ratio.

week0-52
Pre-operative, 24-week post-operatively, and 52-week Olfactory Cleft Scores(NCS)
Időkeret: week0-52

To describe the changes in post-operative Olfactory Cleft Scores(NCS). [NCS: score 0-3, 3 means worse outcome]

week0-52
The number of days of use intranasal corticosteroids (INCS).
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by the number of days of use intranasal corticosteroids (INCS).

week0-52
The proportion of participants who used Systemic glucocorticoids (SCSs) for CRSwNP
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• Proportion of participants who used Systemic glucocorticoids (SCSs) for CRSwNP at least once.

week0-52
Number of days of treatment with Systemic glucocorticoids (SCSs) for CRSwNP.
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• The number of use days that participants used Systemic glucocorticoids (SCSs) for CRSwNP.

week0-52
The proportion of participants who used Systemic glucocorticoids (SCSs) for asthma
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• Proportion of participants who used Systemic glucocorticoids (SCSs) for asthma at least once.

week0-52
The daily dosage of participants used Systemic glucocorticoids (SCSs) for asthma
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• The daily dosage (convert according to the equivalent dose of prednisone.) of participants used Systemic glucocorticoids (SCSs) for asthma

week0-52
Number of days of treatment with Systemic glucocorticoids (SCSs) for asthma.
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• The number of use days that participants used Systemic glucocorticoids (SCSs) for asthma.

week0-52
Number of days of treatment with Antibiotics for CRSwNP
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• The number of use days.

week0-52
Proportion of participants who used Antibiotics for asthma at least once
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• Proportion of participants who used Antibiotics for asthma at least once.

week0-52
Number of days of treatment with Antibiotics for asthma
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• The number of use days.

week0-52
Number of days of treatment with ICS/LABA for asthma
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by

• The number of use days.

week0-52
Proportion of participants who used ICS/LABA/LAMA for asthma at least once.
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by

• Proportion of participants who used at least once.

week0-52
Number of days of treatment with ICS/LABA/LAMA for asthma
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by

• The number of use days.

week0-52
The types of post-operative complications
Időkeret: week0-52

Post-operative complications by

•The types of post-operative complications.

week0-52
The number of post-operative complications occurrences.
Időkeret: week0-52

Post-operative complications by

•The number of complication occurrences.

week0-52
Proportion of participants who used biologics for asthma
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• Proportion of participants who used at least once.

week0-52
The frequency of use biologics for CRSwNP
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• The frequency of use.

week0-52
The frequency of use biologics for asthma
Időkeret: week0-52

To describe the post-operative medication use and need for surgery within one year post-operatively by:

• The frequency of use.

week0-52

Egyéb eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
T2:bEOS≥150 cells/μL or Tissue EOS≥10/hpf or Total IgE≥100 IU/ml.
Időkeret: Baseline

Proportion of different inflammatory subtype at baseline.

Baseline
bEOS: <150,150-300,≥300 cells/μL.
Időkeret: Baseline

Proportion of different inflammatory subtype at baseline.

Baseline
Tissue EOS≥10/hpf.
Időkeret: Baseline

Proportion of different inflammatory subtype at baseline.

Baseline
Total IgE≥100 IU/ml.
Időkeret: Baseline

Proportion of different inflammatory subtype at baseline.

Baseline
Baseline characteristics of patients with recurrence.
Időkeret: Baseline

Explore the characteristics/markers of recurrence within 1 year post-operate: such as gender, age, comorbidities (allergic rhinitis, asthma, NSAID-exacerbated respiratory disease, dermatitis/eczema, COPD, somnipathy etc.), phenotype, pre-operative scores, tissues (eosinophils (count: n/HPF; percentage: %), neutrophils (n/HPF; %) IL-4, IL-5, IL-13, IL-33, IL-17, TNF-α, IFN-γ,IL-25, TGF-β and TSLP ), serum (total IgE and specific IgE (IU/mL), ECP), blood (eosinophils (count: 10^9/L; percentage: %), basophils (10^9/L; %), neutrophils (10^9/L; %), monocytes (10^9/L; %), lymphocytes (10^9/L; %)) and S. aureus abundance

Baseline
Differences in characteristics between patients with clinically meaningful improvement and those without at week-52 and week-4 after surgery.
Időkeret: week-52, week-4

Explore the baseline characteristics and biomarkers related to surgical prognosis of patients:such as gender, age, comorbidities, phenotype, pre- operative scores, S. aureus abundance, different markers in nasal secretions, blood, and tissues

week-52, week-4
Number of participants with AEs, ADRs, and special situations associated with identified AstraZeneca products used for CRSwNP and/or asthma treatment if any.
Időkeret: baseline-week52

To summarize adverse events (AEs), adverse drug reactions (ADRs), and special situations associated with identified AstraZeneca products used for CRSwNP and/or asthma treatment, if any.

baseline-week52
Proportion of participants with AEs, ADRs, and special situations associated with identified AstraZeneca products used for CRSwNP and/or asthma treatment if any.
Időkeret: baseline-week52

To summarize adverse events (AEs), adverse drug reactions (ADRs), and special situations associated with identified AstraZeneca products used for CRSwNP and/or asthma treatment, if any.

baseline-week52
Days of hospitalization
Időkeret: baseline-week52

To describe direct Economic Burden.

baseline-week52
First aid visits
Időkeret: baseline-week52

To describe direct Economic Burden

baseline-week52
General practitioner visits
Időkeret: baseline-week52

To describe direct Economic Burden

baseline-week52
Ear-nose-throat outpatient department visit
Időkeret: baseline-week52

To describe direct Economic Burden

baseline-week52
Total outpatient department visit
Időkeret: baseline-week52

To describe direct Economic Burden

baseline-week52
Outpatient (Expense per visit, Total expense within 1 year post-operatively)
Időkeret: week0-week52

To describe Healthcare Related Utilization

week0-week52
Emergency (Expense per visit, Total expense within 1 year post-operatively)
Időkeret: week0-week52

To describe Healthcare Related Utilization

week0-week52
Inpatient (Expense per visit, Total expense within 1 year post-operatively)
Időkeret: week0-week52

To describe Healthcare Related Utilization

week0-week52
Pharmacy (Expense per visit, Total expense within 1 year post-operatively)
Időkeret: week0-week52

To describe Healthcare Related Utilization

week0-week52
Work productivity and activity impairment (WPAI)
Időkeret: baseline-week52

To describe indirect burden

baseline-week52

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Szponzor

Nyomozók

  • Kutatásvezető: Weiping Wen, Professor, First Affiliated Hospital, Sun Yat-Sen University
  • Kutatásvezető: Dongdong Zhu, Professor, China-Japan Union Hospital, Jilin University

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2026. március 19.

Elsődleges befejezés (Becsült)

2027. október 21.

A tanulmány befejezése (Becsült)

2027. október 21.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. január 26.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. február 27.

Első közzététel (Tényleges)

2026. március 3.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. szeptember 25.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. szeptember 22.

Utolsó ellenőrzés

2026. szeptember 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Egyéb vizsgálati azonosító számok

  • D5242R00005

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

IGEN

IPD terv leírása

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD megosztási időkeret

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-megosztási hozzáférési feltételek

When a request has been approved, AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information

Az IPD megosztását támogató információ típusa

  • STUDY_PROTOCOL

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel